2
|
Lee H, Kim JO, Shim J, Cho M. Multivariate discriminant analysis for branching classification of colonic tubular adenoma glands. CYTOMETRY PART B-CLINICAL CYTOMETRY 2020; 98:429-440. [PMID: 32027469 DOI: 10.1002/cyto.b.21871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/10/2019] [Revised: 01/13/2020] [Accepted: 01/16/2020] [Indexed: 11/08/2022]
Abstract
BACKGROUND Many morphologic findings of histology can be translated into mathematically computerized data, and identifying important parameters is primarily pathologists' task as users. Shape-specific parameters based on computational geometry properties of glands can be used in the field of pathology. We evaluated the diagnostic utility of three shape-specific parameters: the chord intersection ratio, convexity ratio, and maximum concave area ratio for branching classification of glands. METHODS Seven cases of tubular adenoma were studied. After image analysis, segmented neoplastic glands were classified into nonbranching, mild branching, and moderate branching. Using image analysis formulae for the three shape-specific parameters, we compared the values of the parameters with the branching classification results for colonic tubular adenoma. RESULTS Multivariate discriminant analysis was used to classify the branching groups. Classification accuracies of nonbranching, mild branching, and moderate branching group based on the three shape-specific parameters were 98, 94, and 95%, respectively. More branching growth exhibited a higher chord intersection ratio and maximum concave area ratio but lower convexity ratio. We found a statistically significant difference in chord intersection ratio, maximum concave area ratio, and convexity ratio between mild, moderate, and nonbranching groups. Among the three features, the chord intersection ratio was the most significant parameter. CONCLUSIONS Shape-based parameters of chord intersection ratio, convexity ratio, and maximum concave area ratio are valid assessment parameters for irregular branching structures. For the understanding of spatial relationships of histology, the holistic geometric approach using shape-based parameters can be useful.
Collapse
Affiliation(s)
- Hyekyung Lee
- Department of Pathology, College of Medicine, Eulji University, Daejeon, South Korea
| | - Jong O Kim
- Department of Pathology, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
| | - Jaesool Shim
- School of Mechanical Engineering, Yeungnam University, Gyeongsan, Gyeongsangbuk-do, South Korea
| | - Migyung Cho
- Department of Computer & Media Engineering, Tongmyong University, Busan, South Korea
| |
Collapse
|
4
|
Aeffner F, Zarella MD, Buchbinder N, Bui MM, Goodman MR, Hartman DJ, Lujan GM, Molani MA, Parwani AV, Lillard K, Turner OC, Vemuri VNP, Yuil-Valdes AG, Bowman D. Introduction to Digital Image Analysis in Whole-slide Imaging: A White Paper from the Digital Pathology Association. J Pathol Inform 2019; 10:9. [PMID: 30984469 PMCID: PMC6437786 DOI: 10.4103/jpi.jpi_82_18] [Citation(s) in RCA: 184] [Impact Index Per Article: 36.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2018] [Accepted: 12/11/2018] [Indexed: 12/22/2022] Open
Abstract
The advent of whole-slide imaging in digital pathology has brought about the advancement of computer-aided examination of tissue via digital image analysis. Digitized slides can now be easily annotated and analyzed via a variety of algorithms. This study reviews the fundamentals of tissue image analysis and aims to provide pathologists with basic information regarding the features, applications, and general workflow of these new tools. The review gives an overview of the basic categories of software solutions available, potential analysis strategies, technical considerations, and general algorithm readouts. Advantages and limitations of tissue image analysis are discussed, and emerging concepts, such as artificial intelligence and machine learning, are introduced. Finally, examples of how digital image analysis tools are currently being used in diagnostic laboratories, translational research, and drug development are discussed.
Collapse
Affiliation(s)
- Famke Aeffner
- Amgen Inc., Amgen Research, Comparative Biology and Safety Sciences, South San Francisco, CA, USA
| | - Mark D Zarella
- Department of Pathology and Laboratory Medicine, Drexel University, College of Medicine, Philadelphia, PA, USA
| | | | - Marilyn M Bui
- Department of Pathology, Moffitt Cancer Center, Tampa, FL, USA
| | | | | | | | - Mariam A Molani
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA
| | - Anil V Parwani
- The Ohio State University Medical Center, Columbus, OH, USA
| | | | - Oliver C Turner
- Novartis, Novartis Institutes for BioMedical Research, Preclinical Safety, East Hannover, NJ, USA
| | | | - Ana G Yuil-Valdes
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA
| | | |
Collapse
|
5
|
Zarella MD, Bowman; D, Aeffner F, Farahani N, Xthona; A, Absar SF, Parwani A, Bui M, Hartman DJ. A Practical Guide to Whole Slide Imaging: A White Paper From the Digital Pathology Association. Arch Pathol Lab Med 2018; 143:222-234. [DOI: 10.5858/arpa.2018-0343-ra] [Citation(s) in RCA: 150] [Impact Index Per Article: 25.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Context.—
Whole slide imaging (WSI) represents a paradigm shift in pathology, serving as a necessary first step for a wide array of digital tools to enter the field. Its basic function is to digitize glass slides, but its impact on pathology workflows, reproducibility, dissemination of educational material, expansion of service to underprivileged areas, and intrainstitutional and interinstitutional collaboration exemplifies a significant innovative movement with far-reaching effects. Although the benefits of WSI to pathology practices, academic centers, and research institutions are many, the complexities of implementation remain an obstacle to widespread adoption. In the wake of the first regulatory clearance of WSI for primary diagnosis in the United States, some barriers to adoption have fallen. Nevertheless, implementation of WSI remains a difficult prospect for many institutions, especially those with stakeholders unfamiliar with the technologies necessary to implement a system or who cannot effectively communicate to executive leadership and sponsors the benefits of a technology that may lack clear and immediate reimbursement opportunity.
Objectives.—
To present an overview of WSI technology—present and future—and to demonstrate several immediate applications of WSI that support pathology practice, medical education, research, and collaboration.
Data Sources.—
Peer-reviewed literature was reviewed by pathologists, scientists, and technologists who have practical knowledge of and experience with WSI.
Conclusions.—
Implementation of WSI is a multifaceted and inherently multidisciplinary endeavor requiring contributions from pathologists, technologists, and executive leadership. Improved understanding of the current challenges to implementation, as well as the benefits and successes of the technology, can help prospective users identify the best path for success.
Collapse
Affiliation(s)
- Mark D. Zarella
- From the Department of Pathology & Laboratory Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania (Drs Zarella and Absar); Pharma Services, Indica Labs, Inc, Corrales, New Mexico (Mr Bowman); Comparative Biology and Safety Sciences, Amgen, Inc, South San Francisco, California (Dr Aeffner); 3Scan, San Francisco, California (Dr Farahani); Barco, Inc, Beaverton, Oregon (Mr Xt
| | - Douglas Bowman;
- From the Department of Pathology & Laboratory Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania (Drs Zarella and Absar); Pharma Services, Indica Labs, Inc, Corrales, New Mexico (Mr Bowman); Comparative Biology and Safety Sciences, Amgen, Inc, South San Francisco, California (Dr Aeffner); 3Scan, San Francisco, California (Dr Farahani); Barco, Inc, Beaverton, Oregon (Mr Xt
| | - Famke Aeffner
- From the Department of Pathology & Laboratory Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania (Drs Zarella and Absar); Pharma Services, Indica Labs, Inc, Corrales, New Mexico (Mr Bowman); Comparative Biology and Safety Sciences, Amgen, Inc, South San Francisco, California (Dr Aeffner); 3Scan, San Francisco, California (Dr Farahani); Barco, Inc, Beaverton, Oregon (Mr Xt
| | - Navid Farahani
- From the Department of Pathology & Laboratory Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania (Drs Zarella and Absar); Pharma Services, Indica Labs, Inc, Corrales, New Mexico (Mr Bowman); Comparative Biology and Safety Sciences, Amgen, Inc, South San Francisco, California (Dr Aeffner); 3Scan, San Francisco, California (Dr Farahani); Barco, Inc, Beaverton, Oregon (Mr Xt
| | - Albert Xthona;
- From the Department of Pathology & Laboratory Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania (Drs Zarella and Absar); Pharma Services, Indica Labs, Inc, Corrales, New Mexico (Mr Bowman); Comparative Biology and Safety Sciences, Amgen, Inc, South San Francisco, California (Dr Aeffner); 3Scan, San Francisco, California (Dr Farahani); Barco, Inc, Beaverton, Oregon (Mr Xt
| | - Syeda Fatima Absar
- From the Department of Pathology & Laboratory Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania (Drs Zarella and Absar); Pharma Services, Indica Labs, Inc, Corrales, New Mexico (Mr Bowman); Comparative Biology and Safety Sciences, Amgen, Inc, South San Francisco, California (Dr Aeffner); 3Scan, San Francisco, California (Dr Farahani); Barco, Inc, Beaverton, Oregon (Mr Xt
| | - Anil Parwani
- From the Department of Pathology & Laboratory Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania (Drs Zarella and Absar); Pharma Services, Indica Labs, Inc, Corrales, New Mexico (Mr Bowman); Comparative Biology and Safety Sciences, Amgen, Inc, South San Francisco, California (Dr Aeffner); 3Scan, San Francisco, California (Dr Farahani); Barco, Inc, Beaverton, Oregon (Mr Xt
| | - Marilyn Bui
- From the Department of Pathology & Laboratory Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania (Drs Zarella and Absar); Pharma Services, Indica Labs, Inc, Corrales, New Mexico (Mr Bowman); Comparative Biology and Safety Sciences, Amgen, Inc, South San Francisco, California (Dr Aeffner); 3Scan, San Francisco, California (Dr Farahani); Barco, Inc, Beaverton, Oregon (Mr Xt
| | - Douglas J. Hartman
- From the Department of Pathology & Laboratory Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania (Drs Zarella and Absar); Pharma Services, Indica Labs, Inc, Corrales, New Mexico (Mr Bowman); Comparative Biology and Safety Sciences, Amgen, Inc, South San Francisco, California (Dr Aeffner); 3Scan, San Francisco, California (Dr Farahani); Barco, Inc, Beaverton, Oregon (Mr Xt
| |
Collapse
|